News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
795,799 Results
Type
Article (67566)
Company Profile (353)
Press Release (727863)
Multimedia
Podcasts (144)
Webinars (25)
Section
Business (216722)
Career Advice (2437)
Deals (37403)
Drug Delivery (147)
Drug Development (86260)
Employer Resources (181)
FDA (17260)
Job Trends (16031)
News (367551)
Policy (35167)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (3)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (6)
Academia (2974)
Academic (1)
Accelerated approval (51)
Adcomms (32)
Allergies (182)
Alliances (53793)
ALS (222)
Alzheimer's disease (1898)
Antibody-drug conjugate (ADC) (500)
Approvals (17631)
Artificial intelligence (739)
Autoimmune disease (323)
Automation (59)
Bankruptcy (378)
Best Places to Work (12018)
BIOSECURE Act (21)
Biosimilars (230)
Biotechnology (206)
Bladder cancer (199)
Brain cancer (81)
Breast cancer (793)
Cancer (6178)
Cardiovascular disease (506)
Career advice (2069)
Career pathing (48)
CAR-T (348)
CDC (65)
Celiac Disease (3)
Cell therapy (961)
Cervical cancer (50)
Clinical research (74302)
Collaboration (2242)
Company closure (5)
Compensation (1427)
Complete response letters (92)
COVID-19 (2958)
CRISPR (118)
C-suite (1217)
Cystic fibrosis (162)
Data (8275)
Decentralized trials (3)
Denatured (43)
Depression (177)
Dermatology (93)
Diabetes (616)
Diagnostics (7242)
Digital health (59)
Diversity (12)
Diversity, equity & inclusion (46)
Drug discovery (353)
Drug pricing (222)
Drug shortages (34)
Duchenne muscular dystrophy (301)
Earnings (94696)
Editorial (76)
Employer branding (22)
Employer resources (161)
Events (126384)
Executive appointments (1150)
FDA (21141)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (35)
Funding (1833)
Gene editing (253)
Generative AI (62)
Gene therapy (778)
GLP-1 (1146)
Government (5077)
Grass and pollen (8)
Guidances (412)
Healthcare (19966)
HIV (84)
Huntington's disease (58)
IgA nephropathy (103)
Immunology and inflammation (312)
Immuno-oncology (103)
Indications (198)
Infectious disease (3325)
Inflammatory bowel disease (227)
Inflation Reduction Act (14)
Influenza (142)
Intellectual property (304)
Interviews (417)
IPO (17122)
IRA (57)
Job creations (4323)
Job search strategy (1720)
JPM (66)
Kidney cancer (19)
Labor market (105)
Layoffs (619)
Leadership (45)
Legal (8644)
Liver cancer (105)
Longevity (35)
Lung cancer (809)
Lymphoma (443)
Machine learning (63)
Management (63)
Manufacturing (1121)
MASH (213)
Medical device (14307)
Medtech (14439)
Mergers & acquisitions (21544)
Metabolic disorders (1608)
mRNA (242)
Multiple sclerosis (196)
NASH (18)
Neurodegenerative disease (460)
Neuropsychiatric disorders (116)
Neuroscience (3526)
Neurotech (1)
NextGen: Class of 2026 (6904)
Non-profit (4916)
Now hiring (79)
Obesity (750)
Opinion (330)
Ovarian cancer (233)
Pain (279)
Pancreatic cancer (319)
Parkinson's disease (391)
Partnered (35)
Patents (619)
Patient recruitment (712)
Peanut (66)
People (63570)
Pharmaceutical (87)
Pharmacy benefit managers (35)
Phase 1 (23076)
Phase 2 (32564)
Phase 3 (24305)
Pipeline (9215)
Policy (359)
Postmarket research (3012)
Preclinical (10357)
Press Release (71)
Prostate cancer (324)
Psychedelics (62)
Radiopharmaceuticals (353)
Rare diseases (1159)
Real estate (6719)
Recruiting (73)
Regulatory (27158)
Reports (57)
Research institute (2736)
Resumes & cover letters (400)
Rett syndrome (40)
RNA editing (24)
RSV (92)
Schizophrenia (191)
Series A (305)
Series B (220)
Service/supplier (17)
Sickle cell disease (116)
Special edition (29)
Spinal muscular atrophy (176)
Sponsored (51)
Startups (3968)
State (2)
Stomach cancer (19)
Supply chain (134)
Tariffs (100)
The Weekly (99)
Vaccines (1207)
Venture capital (115)
Weight loss (494)
Women's health (132)
Worklife (21)
Date
Today (1)
Last 7 days (623)
Last 30 days (3272)
Last 365 days (31104)
2026 (14153)
2025 (31227)
2024 (36431)
2023 (41374)
2022 (52681)
2021 (57263)
2020 (55950)
2019 (48861)
2018 (36951)
2017 (34396)
2016 (34513)
2015 (41016)
2014 (35078)
2013 (31273)
2012 (32780)
2011 (33162)
2010 (31793)
Location
Africa (949)
Alabama (97)
Alaska (7)
Arizona (373)
Arkansas (16)
Asia (45688)
Australia (7798)
California (13731)
Canada (3880)
China (1448)
Colorado (585)
Connecticut (598)
Delaware (423)
Europe (101607)
Florida (2047)
Georgia (444)
Hawaii (3)
Idaho (64)
Illinois (1129)
India (96)
Indiana (625)
Iowa (24)
Japan (570)
Kansas (136)
Kentucky (53)
Louisiana (46)
Maine (76)
Maryland (1646)
Massachusetts (9901)
Michigan (376)
Minnesota (752)
Mississippi (6)
Missouri (146)
Montana (36)
Nebraska (29)
Nevada (149)
New Hampshire (86)
New Jersey (3590)
New Mexico (33)
New York (3625)
North Carolina (1805)
North Dakota (11)
Northern California (6884)
Ohio (416)
Oklahoma (25)
Oregon (47)
Pennsylvania (2747)
Puerto Rico (29)
Rhode Island (50)
South America (1310)
South Carolina (88)
South Dakota (2)
Southern California (5417)
Tennessee (219)
Texas (2201)
United States (48727)
Utah (413)
Vermont (1)
Virginia (348)
Washington D.C. (85)
Washington State (1106)
West Virginia (4)
Wisconsin (143)
Wyoming (2)
795,799 Results for "kyowa kirin pharmaceutical research inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Autoimmune disease
Amgen Ends Autoimmune Alliance With Kyowa Kirin Amid Safety, Efficacy Questions
A Phase III readout in September 2024 for rocatinlimab, on which Amgen and Kyowa Kirin were collaborating in atopic dermatitis, appeared underwhelming to analysts, with Jefferies noting that the data “came in at the lower end of efficacy and expectations.”
February 2, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
May 12, 2026
·
14 min read
Press Releases
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
April 24, 2026
·
14 min read
Rare diseases
Kyowa Kirin Could Get Windfall From Updated Newborn Screening Recommendations
A report from analysts at Jefferies suggested that new screenings for metachromatic leukodystrophy and Duchenne muscular dystrophy could bump sales of the gene therapy Libmeldy by more than $100 million.
December 19, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
February 1, 2026
·
5 min read
Press Releases
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region
November 3, 2025
·
3 min read
Press Releases
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
October 30, 2025
·
3 min read
Press Releases
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
December 11, 2025
·
4 min read
Press Releases
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
October 27, 2025
·
3 min read
Press Releases
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
December 9, 2025
·
17 min read
1 of 79,580
Next
